Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"

The company's flagship product is a fast-acting gel for erectile dysfunction
Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"
The company's condom range received regulatory sign-off in Kuwait recently

The phase III clinical trial of Futura Medical PLC's (LONFUM) fast-onset gel for erectile dysfunction is on track for first patient dosing in September, chairman John Clarke confirmed ahead of the company's annual meeting later.

He added that the completion of a significant out-licensing agreement for MED2002 "remains a top priority" as he investors were told: "Whilst negotiations proceed, we will continue to maintain the momentum in the product's development.

READ: Futura Medical starts work on Phase III trial for its erectile dysfunction gel

In an update on progress, Clarke said preparations for the launch of its CSD500 condom in new territories were underway after it received regulatory sign-off in Kuwait and with the product now on sale in Saudi Arabia. 

On TPR100, Futura's diclofenac gel for pain relief, the chairman said the company was waiting for the manufacturer Thornton & Ross to submit its UK regulatory dossier to the Medicines & Healthcare products Regulatory Agency.

"Futura has a strong balance sheet, an experienced team, an exciting product portfolio and a particularly valuable asset in MED2002, which has the potential to be the world's fastest-acting erectile dysfunction treatment," said Clarke.  

"We look forward to providing further updates in the current financial year."


View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use